Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

Cited by papers we hold 5

• Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment · 2023
  No notice
• Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer · 2022
  No notice
• CAR T cells in solid tumors: challenges and opportunities · 2021
  No notice
• IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin · 2021
  No notice
• Gene modification strategies for next-generation CAR T cells against solid cancers · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.